Yi Larson - 01 Dec 2021 Form 4 Insider Report for LianBio (LIANY)

Reporting relationship: Chief Financial Officer
Issuer ticker: LIANY
Reported as of: 01 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Dec 2021, 15:05:10 UTC
Prior SEC filing: 01 Nov 2021
Next SEC filing: 17 Jun 2022
Source filing: View source filing
Reporting owner signature: By: /s/ Angela Chen, Attorney-in-Fact

Key filing fact

Yi Larson filed Form 4 for LianBio (LIANY) on 03 Dec 2021.

Key facts

This page summarizes Yi Larson's Form 4 filing for LianBio (LIANY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Dec 2021, 15:05.

Change

Previous filing in this sequence was filed on 01 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LIAN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +5,996
Change %: +0.5%
Price: $0.000000
Shares after: 1,202,841
Date: 01 Dec 2021
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 5,996
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying the option shall vest and become exercisable on December 1, 2022; the remainder shall vest and become exercisable in three equal annual installments such that the option shall be fully vested on December 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.